Activating JAK2 mutants reveal cytokine receptor coupling differences that impact outcomes in myeloproliferative neoplasm

Leukemia

Volumn 31, Issue 10, 2017, Pages 2122-2131

  Yao, H ^a   Ma, Y ^a   Hong, Z ^a   Zhao, L ^a   Monaghan, S A ^a   Hu, M C ^a   Huang, L J ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE RECEPTOR; CYTOKINE RECEPTOR EPOR; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; JANUS KINASE 2; UNCLASSIFIED DRUG; ERYTHROPOIETIN RECEPTOR; HYBRID PROTEIN; JAK2 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD ANALYSIS; CELL LINEAGE; CELL POPULATION; COLONY FORMING UNIT; CONTROLLED STUDY; ENZYME ACTIVATION; ERYTHROID CELL; FLOW CYTOMETRY; GRANULOCYTE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; IN VITRO STUDY; JAK-STAT SIGNALING; MOUSE; MTT ASSAY; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; BAGG ALBINO MOUSE; CELL DIVISION; CELL LINE; COMPARATIVE STUDY; ENZYMOLOGY; ERYTHROPOIESIS; EXON; GENETIC TRANSDUCTION; GENETICS; HEMATOPOIETIC STEM CELL; METABOLISM; MISSENSE MUTATION; MYELOPOIESIS; MYELOPROLIFERATIVE DISORDER; PATHOLOGY; PHYSIOLOGY; POINT MUTATION; PROTEIN ANALYSIS; RADIATION CHIMERA; REPORTER GENE; TUMOR STEM CELL ASSAY;

ANIMALS; CELL DIVISION; CELL LINE; CELL LINEAGE; ENZYME ACTIVATION; ERYTHROPOIESIS; EXONS; GENES, REPORTER; HEMATOPOIETIC STEM CELLS; HUMANS; JANUS KINASE 2; MICE; MICE, INBRED BALB C; MUTATION, MISSENSE; MYELOPOIESIS; MYELOPROLIFERATIVE DISORDERS; PHENOTYPE; POINT MUTATION; PROTEIN INTERACTION MAPPING; RADIATION CHIMERA; RECEPTORS, ERYTHROPOIETIN; RECEPTORS, GRANULOCYTE COLONY-STIMULATING FACTOR; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; TRANSDUCTION, GENETIC; TUMOR STEM CELL ASSAY;

EID: 85011004567     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2017.1     Document Type: Article

References (43)

1. Thomas SJ, Snowden JA, Zeidler MP, Danson SJ. The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br J Cancer 2015; 113: 365-371
2. Vainchenker W, Constantinescu SN. JAK/STAT signaling in hematological malignancies. Oncogene 2013; 32: 2601-2613
3. Villarino AV, Kanno Y, Ferdinand JR, O'Shea JJ. Mechanisms of Jak/STAT signaling in immunity and disease. J Immunol 2015; 194: 21-27
4. Stark GR, Darnell JE Jr. The JAK-STAT pathway at twenty. Immunity 2012; 36: 503-514
5. Levine RL. JAK-mutant myeloproliferative neoplasms. Curr Top Microbiol Immunol 2012; 355: 119-133
6. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061
7. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148
8. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-offunction mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790
9. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-397
10. Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005; 280: 22788-22792
11. Mullally A, Lane SW, Brumme K, Ebert BL. Myeloproliferative neoplasm animal models. Hematol Oncol Clin North Am 2012; 26: 1065-1081
12. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356: 459-468
13. Grisouard J, Li S, Kubovcakova L, Rao TN, Meyer SC, Lundberg P, et al. JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis. Blood 2016; 128: 839-851
14. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366: 799-807
15. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012; 366: 787-798
16. Lu X, Huang LJ, Lodish HF. Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F. J Biol Chem 2008; 283: 5258-5266
17. Lu X, Levine R, Tong W, Wernig G, Pikman Y, Zarnegar S, et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci USA 2005; 102: 18962-18967
18. Pradhan A, Lambert QT, Griner LN, Reuther GW. Activation of JAK2-V617F by components of heterodimeric cytokine receptors. J Biol Chem 2010; 285: 16651-16663
19. Staerk J, Kallin A, Demoulin JB, Vainchenker W, Constantinescu SN. JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor. J Biol Chem 2005; 280: 41893-41899
20. Bercovich D, Ganmore I, Scott LM, Wainreb G, Birger Y, Elimelech A, et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 2008; 372: 1484-1492
21. Malinge S, Ben-Abdelali R, Settegrana C, Radford-Weiss I, Debre M, Beldjord K, et al. Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. Blood 2007; 109: 2202-2204
22. Zhao L, Dong H, Zhang CC, Kinch L, Osawa M, Iacovino M, et al. A JAK2 interdomain linker relays Epo receptor engagement signals to kinase activation. J Biol Chem 2009; 284: 26988-26998
23. Kiel MJ, Yilmaz OH, Iwashita T, Terhorst C, Morrison SJ. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 2005; 121: 1109-1121
24. Akashi K, Traver D, Miyamoto T, Weissman IL. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 2000; 404: 193-197
25. Liu Y, Pop R, Sadegh C, Brugnara C, Haase VH, Socolovsky M. Suppression of Fas-FasL coexpression by erythropoietin mediates erythroblast expansion during the erythropoietic stress response in vivo. Blood 2006; 108: 123-133
26. Sulahian R, Cleaver O, Huang LJ. Ligand-induced EpoR internalization is mediated by JAK2 and p85 and is impaired by mutations responsible for primary familial and congenital polycythemia. Blood 2009; 113: 5287-5297
27. Li J, Kent DG, Chen E, Green AR. Mouse models of myeloproliferative neoplasms: JAK of all grades. Dis Model Mech 2011; 4: 311-317
28. Skoda RC. Less Jak2 makes more platelets. Blood 2014; 124: 2168-2169
29. Koulnis M, Porpiglia E, Hidalgo D, Socolovsky M. Erythropoiesis: from molecular pathways to system properties. Adv Exp Med Biol 2014; 844: 37-58
30. Koury MJ, Bondurant MC. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 1990; 248: 378-381
31. Panopoulos AD, Watowich SS. Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and 'emergency' hematopoiesis. Cytokine 2008; 42: 277-288
32. Richards MK, Liu F, Iwasaki H, Akashi K, Link DC. Pivotal role of granulocyte colonystimulating factor in the development of progenitors in the common myeloid pathway. Blood 2003; 102: 3562-3568
33. Funakoshi-Tago M, Pelletier S, Matsuda T, Parganas E, Ihle JN. Receptor specific downregulation of cytokine signaling by autophosphorylation in the FERM domain of Jak2. EMBO J 2006; 25: 4763-4772
34. Funakoshi-Tago M, Pelletier S, Moritake H, Parganas E, Ihle JN. Jak2 FERM domain interaction with the erythropoietin receptor regulates Jak2 kinase activity. Mol Cell Biol 2008; 28: 1792-1801
35. Nelson EA, Sharma SV, Settleman J, Frank DA. A chemical biology approach to developing STAT inhibitors: molecular strategies for accelerating clinical translation. Oncotarget 2011; 2: 518-524
36. Zhang J, Socolovsky M, Gross AW, Lodish HF. Role of Ras signaling in erythroid differentiation of mouse fetal liver cells: functional analysis by a flow cytometrybased novel culture system. Blood 2003; 102: 3938-3946
37. Scott LM. The JAK2 exon 12 mutations: a comprehensive review. Am J Hematol 2011; 86: 668-676
38. Scott LM, Scott MA, Campbell PJ, Green AR. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 2006; 108: 2435-2437
39. Kilpivaara O, Levine RL. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Leukemia 2008; 22: 1813-1817
40. Chen E, Beer PA, Godfrey AL, Ortmann CA, Li J, Costa-Pereira AP, et al. Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell 2010; 18: 524-535
41. Walz C, Ahmed W, Lazarides K, Betancur M, Patel N, Hennighausen L, et al. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. Blood 2012; 119: 3550-3560
42. Yan D, Hutchison RE, Mohi G. Critical requirement for Stat5 in a mouse model of polycythemia vera. Blood 2012; 119: 3539-3549
43. Choong ML, Pecquet C, Pendharkar V, Diaconu CC, Yong JW, Tai SJ, et al. Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors. J Cell Mol Med 2013; 17: 1397-1409